Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HAE vs THOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HAE Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

HAE Overall Winner 6-Pillar Tally: HAE 5 – 0 THOR (1 Tie) Matrix Metrics: HAE 9 – 1 THOR

As of Nov 20, 2026, Haemonetics Corporation (HAE) is the stronger overall head-to-head candidate over THOR (THOR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HAE carries a Unified Composite Score of 49.2/100 (HOLD) at $120.16 (22.7x Forward P/E, 18.8% operating margin), whereas THOR carries 44.5/100 (HOLD) at $24.63 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: HAE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 52.1); meanwhile THOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HAE vs THOR
HAE NYSE Head-to-Head Winner
Haemonetics Corporation
Surgical & Medical Instruments & Apparatus
$120.16
-0.17% 1D
Market Cap $5.5B
TTM Revenue $1.38B
Forward P/E 22.7x
Beta / 30D Vol 0.28β · 33% Vol
Unified Composite Score
49.2 / 100 HOLD
Tech 40.0 Fund 38.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.6% over 20 days), RSI 52
RSI-14: 52.1 · SMA20: $121.06 · SMA50: $115.17
THOR US Equity
THOR
Institutional Equity
$24.63
-1.7% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.46β · 17% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 27.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.0%), weak momentum, RSI 32
RSI-14: 31.7 · SMA20: $25.77 · SMA50: $25.60

6-Pillar Scorecard Institutional Category Breakdown (HAE 5 – 0 THOR)

Columns: Metric · HAE · THOR
1. Valuation Multiples HAE
Forward P/E 22.7x N/M
Trailing P/E 53.3x N/M
PEG Ratio 1.92x N/M
EV / Revenue 4.0x N/M
2. Growth & Scale HAE
Revenue Growth (YoY) +9.3% N/A
Earnings Growth (YoY) +23.5% N/A
TTM Revenue (USD) $1.38B N/A
Market Cap $5.5B N/A
3. Profitability & Quality HAE
Gross Margin 59.8% N/A
Operating Margin 18.8% N/A
Net Profit Margin 7.5% N/A
Return on Equity (ROE) 11.9% N/A
4. Balance Sheet & Cash Flow HAE
Cash Generation (TTM) $364M EBITDA N/A
Cash Flow Margin 26.3% EBITDA Mgn N/A
Net Cash / Leverage $19.74 Book/Sh · 11.9% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 32.7% (2nd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat HAE
OpEx & R&D Intensity 41.0% of Rev ($567M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HAE (9) vs THOR (1)
Institutional Metric HAE THOR Criterion Row Edge
Market Capitalization
Scale
$5.5B N/A Larger Scale HAE
Trailing P/E Ratio
Valuation
53.3x N/M Lower Multiple HAE
Forward P/E Ratio
Valuation
22.7x N/M Lower Multiple HAE
Revenue Growth (YoY)
Growth
+9.3% N/A Higher Growth HAE
Operating Margin (TTM)
Profitability
18.8% N/A Higher Margin HAE
Net Profit Margin
Profitability
7.5% N/A Higher Margin HAE
Return on Equity (ROE)
Capital Efficiency
11.9% N/A Higher ROE HAE
52-Week Range Position
Momentum
85% ($51–$132) 2% ($25–$29) Stronger Trend HAE
Beta / 30D Volatility
Risk Regime
0.28β · 33% Vol 0.46β · 17% Vol Lower Realized Risk THOR
Unified Institutional Score
Composite Signal
49.2 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite HAE
Trailing 12M Revenue (USD)
Operating Scale
$1.38B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
59.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.92x PEG · 4.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$364M EBITDA ($19.74 Book/Sh · 11.9% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HAE +7.36 pp
HAE: +3.44% · THOR: -3.92%
3M Horizon HAE +18.31 pp
HAE: +10.85% · THOR: -7.46%
6M Horizon HAE +66.53 pp
HAE: +65.1% · THOR: -1.43%
1Y Horizon HAE +66.53 pp
HAE: +65.1% · THOR: -1.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HAE vs THOR. Trailing 12-month operating profitability (HAE 18.8% vs THOR N/A) and valuation multiples (HAE 22.7x vs THOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

HAE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.38B
Gross Margin59.8%
Op. Margin18.8%
ROE / Fwd P/E11.9% · 22.7x
THOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HAE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 32.7%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HAE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
THOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact THOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HAE Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $5.5B market capitalization and 18.8% operating margin.
OpEx & R&D Reinvestment 41.0% of Rev ($567M)
90D Engineering Disclosures 0 Published
THOR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HAE vs THOR Key Questions & Quantitative Answers

As of Nov 20, 2026, Haemonetics Corporation (HAE) is the stronger overall head-to-head candidate over THOR (THOR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HAE carries a Unified Composite Score of 49.2/100 (HOLD) at $120.16 (22.7x Forward P/E, 18.8% operating margin), whereas THOR carries 44.5/100 (HOLD) at $24.63 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: HAE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 52.1); meanwhile THOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HAE leads the Growth & Scale pillar: HAE posts +9.3% YoY revenue growth and +23.5% YoY earnings growth on $1.38B TTM revenue (59.8% gross margin, 18.8% operating margin), compared with THOR at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, HAE generates $1.38B in USD-normalized revenue versus N/A for THOR. In operating R&D and SG&A reinvestment, HAE deploys 41.0% of Rev ($567M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for THOR.

HAE screens cheaper on headline valuation multiples. HAE trades at 22.7x Forward P/E, 53.3x Trailing P/E, 1.92x PEG, and 4.0x EV/Revenue (26.3% EBITDA margin), whereas THOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HAE (11.9% ROE) versus THOR (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, HAE carries 32.7% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 33% Vol realized risk). By comparison, THOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 17% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.